CORDIS
EU research results

CORDIS

English EN
Novel drug delivery system produced by centrifugal technologies – composed to minimize adverse immune reactions and designed for optimised therapeutic effects

Novel drug delivery system produced by centrifugal technologies – composed to minimize adverse immune reactions and designed for optimised therapeutic effects

Objective

Drug delivery systems are a matter of intensive scientific investigation and technological developments. They are necessary since many active pharmaceutical ingredients to be employed in therapy, diagnostics or vaccination cause serious side effects when distributed non-specifically. Without a drug delivery system, the active pharmaceutical ingredients may accumulate in healthy and sensitive tissue, provoke adverse immune reactions, have poor solubility, low bioavailability and inefficient targeting.
To meet these challenges, the key objectives of the proposed project are the development and testing of an innovative production technology for nanocapsules as a drug delivery system using centrifugation, colloidal and fluid mechanical techniques. These novel nanocapsules should be especially suited for proteins and other sensitive biomolecules which are vulnerable to degradation by existing encapsulation technologies. An immune protection consisting of a suitable polymer cover of the nanocapsules has to be developed to enable long circulation in human blood without provoking innate immune reactions by the complement, the coagulation and the phagocytic systems. Other than established polymer protection systems, the novel polymer protection should not be immunogenic to avoid accelerated blood clearance upon repeated administration. The nanocapsules have to prove to be sufficiently stable in human blood ex vivo. In vitro and in vivo tests in cancer models will be performed to compare drug efficiency, immune reactions and organ distribution of encapsulated and non encapsulated active pharmaceutical ingredients. Multidisciplinary research and innovation for nanomedicine is aimed for by collaboration in an intersectoral research team comprising mechanical and process engineering, pharmaceutical technology, immunology and cancer research.

Coordinator

ABNOBA GMBH

Address

Hohenzollernstrasse 16
75177 Pforzheim

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 481 842,40

Administrative Contact

Gero Leneweit (Dr.)

Participants (3)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 464 451,69

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 272 463,21

KARLSRUHER INSTITUT FUER TECHNOLOGIE

Germany

EU Contribution

€ 273 787,80

Project information

Grant agreement ID: 324275

Status

Closed project

  • Start date

    1 April 2013

  • End date

    31 March 2017

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 1 492 545,10

  • EU contribution

    € 1 492 545,10

Coordinated by:

ABNOBA GMBH

Germany

This project is featured in...